National Research is a health information services business based in the US. National Research shares (NRC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $19.14 – a decrease of 4.25% over the previous week. National Research employs 435 staff and has a trailing 12-month revenue of around $144.2 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $19.14 |
|---|---|
| 52-week range | $17.62 - $41.68 |
| 50-day moving average | $20.28 |
| 200-day moving average | $28.13 |
| Wall St. target price | N/A |
| PE ratio | 18.0667 |
| Dividend yield | $0.48 (2.36%) |
| Earnings per share (TTM) | $1.05 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $19.14 from 2024-11-15
| 1 week (2024-11-08) | -4.25% |
|---|---|
| 1 month (2024-10-16) | -1.59% |
| 3 months (2024-08-16) | -8.94% |
| 6 months (2024-05-16) | -39.89% |
| 1 year (2023-11-16) | -53.73% |
|---|---|
| 2 years (2022-11-16) | -46.34% |
| 3 years (2021-11-16) | 42.7668 |
| 5 years (2019-11-15) | 56.5739 |
Valuing National Research stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of National Research's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
National Research's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, National Research shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
National Research's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $43.3 million.
The EBITDA is a measure of a National Research's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $144.2 million |
|---|---|
| Operating margin TTM | 22.29% |
| Gross profit TTM | $94.5 million |
| Return on assets TTM | 18.53% |
| Return on equity TTM | 58.56% |
| Profit margin | 18.79% |
| Book value | $1.48 |
| Market Capitalization | $476.6 million |
TTM: trailing 12 months
Dividend payout ratio: 42.74% of net profits
Recently National Research has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), National Research shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In National Research's case, that would currently equate to about $0.48 per share.
While National Research's payout ratio might seem fairly standard, it's worth remembering that National Research may be investing much of the rest of its net profits in future growth.
National Research's most recent dividend payout was on 9 January 2025. The latest dividend was paid out to all shareholders who bought their shares by 26 December 2024 (the "ex-dividend date").
Over the last 12 months, National Research's shares have ranged in value from as little as $17.62 up to $41.6779. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while National Research's is 0.532. This would suggest that National Research's shares are less volatile than average (for this exchange).
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska. .
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.